Paul F. Vollebregt

Paul F. Vollebregt

Auto-generated profile, based on publicly available information

Paul F. Vollebregt

Department of Hepatology and Gastroenterology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Centre, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2021 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
PHPaul T. Heitmann
Paul T. Heitmann
PVPaul F. Vollebregt
Paul F. Vollebregt
CKCharles Knowles
Charles Knowles
PLPeter J. Lunniss
Peter J. Lunniss
PDPhil G. Dinning
Phil G. Dinning
MSMark Scott
Mark Scott

9 March 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
PVP. F. Vollebregt
P. F. Vollebregt
ABA. A. van Bodegraven
A. A. van Bodegraven
TKT. M. L. Markus‐De Kwaadsteniet
T. M. L. Markus‐De Kwaadsteniet
DHD. van der Horst
D. van der Horst
RFR. J. F. Felt‐Bersma
R. J. F. Felt‐Bersma
Summary: Background: Patient reported outcomes regarding perianal disease and faecal incontinence in the community‐based inflammatory bowel disease population are poorly described.Aims: To determine the impacts of perianal disease and faecal incontinence on quality of life and employment in inflammatory bowel disease patients.Methods: For this cross‐sectional study, a comprehensive survey was sent out to members of the Dutch National Crohn's and Colitis patient organisation. Validated questionnaires regarding faecal incontinence and active perianal disease were used to estimate its prevalence's. The effect on the quality of life (36‐Item Short Form Survey) and on employment status (multivariate binary regression analysis) was assessed in this inflammatory bowel disease population.Results: A total number of 1092 returned questionnaires (58% responders) were used for analysis; 750 respondents (69%) were female; mean age was 47 years (IQR 35‐59). In 621 patients (57%) Crohn's disease, in 422 (39%) ulcerative colitis and in 49 (4%) patients unclassifiable inflammatory bowel disease was self‐reported. The 114 patients (10%) with a stoma were excluded for continence related analyses. Faecal incontinence was reported in 555 patients (57%), was comparable between the different inflammatory bowel disease diagnoses and affected all 36‐Item Short Form Survey subscales adversely (incontinence vs continence: Physical functioning 75 vs 84, P < 0.0001; Limitations due to physical health 49 vs 63, P < 0.0001; Limitations due to emotional problems 49 vs 64, P < 0.0001; Energy/fatigue 47 vs 53, P < 0.0001; Emotional well‐being 71 vs 74, P = 0.005; Social functioning 63 vs 73, P < 0.0001; Pain 66 vs 75, P < 0.0001; General health 41 vs 48, P < 0.0001). Active perianal disease was reported in 39% Crohn's disease, 16% ulcerative colitis (84% fissures) and 20% unclassifiable inflammatory bowel disease patients. Faecal incontinence was more common in patients with perianal disease (67% vs 53%, P = 0.003). When correcting for age, disease duration, inflammatory bowel disease‐related surgery and faecal incontinence, active perianal disease was independently affecting employment (OR 0.67; 95% CI 0.50–0.91; P = 0.01).Conclusions: Faecal incontinence and perianal disease are quality of life determining factors. Faecal incontinence needs more attention among clinicians, and development of new (drug) therapies needs to be focussed on perianal disease.

13 January 2019 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
PVPaul F. Vollebregt
Paul F. Vollebregt
ARAnnika M. P. Rasijeff
Annika M. P. Rasijeff
DPDavid Parés
David Parés
Ugo GrossiUgo Grossi
Ugo Grossi
ECEmma V. Carrington
Emma V. Carrington
MSMark Scott
Mark Scott

7 May 2021 in BJS Open
Verified
Journal Article
Open access
PCP Chaichanavichkij
P Chaichanavichkij
PVP F Vollebregt
P F Vollebregt
STS Z Y Tee
S Z Y Tee
MSMark Scott
Mark Scott
CKCharles Knowles
Charles Knowles
Background: Colectomy remains a treatment option for a minority of patients with slow-transit constipation (STC) refractory to conservative treatment. However careful patient selection is essential to maximize benefits and minimize risk of adverse outcome. This study determined the proportion of patients with chronic constipation that would meet criteria for colectomy based on recent European graded practice recommendations derived by expert consensus. Methods: Retrospective application of graded practice recommendations was undertaken on a prospectively maintained data set of consecutive adult patients with chronic constipation who underwent whole-gut transit studies using radio-opaque markers. Primary analysis applied contraindications achieving high level of expert consensus (normal whole-gut transit as an absolute contraindication and faecal incontinence as a relative contraindication for colectomy). Secondary analysis applied contraindications with less certain consensus. Results: Primary analysis of 1568 patients undergoing a whole-gut transit study between January 2004 and March 2016 found 208 (13.3 per cent) met published criteria to be selected for colectomy, with 974 excluded for normal whole-gut transit and 386 for faecal incontinence. Secondary analysis demonstrated high prevalence of other relative contraindications to colectomy: 165 concomitant upper gastrointestinal symptoms, 216 abdominal pain (including 126 irritable bowel syndrome), and 446 evacuation disorder. The majority of patients (416 of 594) had two or more relative contraindications. If these patients were excluded, only 26 (1.7 per cent) chronically constipated patients retrospectively met selection criteria for colectomy. Conclusions: The retrospective application of selection criteria is a limitation. However, the data highlight the high prevalence of factors associated with poor postoperative outcome and provide further caution to surgeons undertaking colectomy for STC.

5 July 2016 in Techniques in Coloproctology
Verified
Journal Article
Closed access
PDF file
PVP. F. Vollebregt
P. F. Vollebregt
AEA. K. E. Elfrink
A. K. E. Elfrink
WMW. J. H. J. Meijerink
W. J. H. J. Meijerink
RFR. J. F. Felt-Bersma
R. J. F. Felt-Bersma

27 June 2022 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
ACAnisa Choudhary
Anisa Choudhary
PVPaul F. Vollebregt
Paul F. Vollebregt
QAQasim Aziz
Qasim Aziz
SSS. Mark Scott
S. Mark Scott
AFAsma Fikree
Asma Fikree
Summary: Background and Aims: To evaluate symptom presentation and underlying pathophysiology of colonic/anorectal dysfunction in females with functional constipation (FC) and hypermobile Ehlers–Danlos syndrome (hEDS)/hypermobility spectrum disorder (HSD)Methods: Case–control study of 67 consecutive female patients with an established diagnosis of hEDS/HSD referred to a specialist centre for investigation of FC (Rome III criteria), age‐matched (1:2 ratio) to 134 female controls with FC scoring 0 on the validated 5‐point joint hypermobility questionnaire. Symptoms and results of colonic/anorectal physiology testing were compared. An independent series of 72 consecutive females with hEDS/HSD, referred to a separate hospital for investigation of FC, was used to validate physiological findings.Results: Females with hEDS/HSD were more likely to report constipation for ≥ 5 years (76.1% vs. 61.2%, p = 0.035), and a greater proportion had a high Cleveland Clinic constipation score (≥12: 97.0% vs. 87.3%; p = 0.027). The proportions with delayed whole‐gut transit were similar between groups (35.3% vs. 41.7%; p = 0.462), as were the proportions with functional or structural abnormalities on defaecography (functional: 47.8% vs. 36.6%; p = 0.127; structural: 65.7% vs. 66.4%; p = 0.916). However, rectal hyposensitivity was more common in those with hEDS/HSD (43.3% vs. 20.1%; p = 0.0006); this was confirmed in the validation cohort (rectal hyposensitivity: 45.8%).Conclusions: Rectal hyposensitivity is a common pathophysiological factor in females with FC and hEDS/HSD as confirmed in two separate cohorts. The rectal hyposensitivity may be due to altered rectal biomechanics/neuronal pathway dysfunction. Management may be better focused on enhancement of sensory perception (e.g., sensory biofeedback).